(RTTNews) - Orexo AB, (ORXOY.OB) a Swedish pharmaceutical company Friday announced positive data from a clinical study of OX640, a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions.
The company said OX640 treatments achieved clinically relevant plasma levels of epinephrine compared to the intramuscular reference product. Moreover, the pharmacokinetic and pharmacodynamic evaluation in subjects with and without allergic rhinitis supported rapid onset of effect in patients with airway symptoms.
OX640 formulations typically produced more pronounced increases in blood pressure and heart rate than the intramuscular injection, which are key effects for the treatment of anaphylaxis. There were no severe or serious adverse events.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%20Declares%20%240.11%20Dividend%20%7C%20Nasdaq&_biz_n=0&rnd=800680&cdn_o=a&_biz_z=1743623783662)
